Sevelamer carbonate and calcium acetate are both medications used to manage hyperphosphatemia in patients with chronic kidney disease (CKD) but are distinct compounds with different mechanisms of action and properties.
How do sevelamer carbonate and calcium acetate work?
Sevelamer carbonate is an ion-exchange resin that binds to phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [1]. It does not contain a metal component. Calcium acetate, on the other hand, is a calcium salt that also binds to dietary phosphate in the gut, but it does so by forming insoluble calcium phosphate [1].
What are the differences in their use and potential side effects?
Because calcium acetate contains calcium, its use can lead to increased calcium levels in the body. This can be a concern for patients who may already have high calcium levels or are at risk for calcification of tissues [1]. Sevelamer carbonate does not introduce additional calcium into the body, which can be an advantage in certain patient populations [1]. However, both medications can cause gastrointestinal side effects such as nausea, vomiting, and constipation [1].
When might doctors choose one over the other?
The choice between sevelamer carbonate and calcium acetate often depends on individual patient factors, including their serum calcium levels, risk of hypercalcemia, and potential for vascular calcification. Physicians may prefer sevelamer carbonate for patients at risk of calcium overload or accumulation [1].
Are there other phosphate binders available?
Yes, other phosphate binders exist, including other non-calcium-based binders like lanthanum carbonate and iron-based binders. These alternatives offer different profiles regarding efficacy, side effects, and cost, providing various options for managing hyperphosphatemia [1]. DrugPatentWatch.com tracks patents and exclusivity for these and other pharmaceutical products.